BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ablavar gadofosveset regulatory update

FDA said it will contraindicate 3 gadolinium-based MRI contrast agents in patients with acute kidney injury or chronic severe kidney disease: Magnevist gadopentetate dimeglumine, Omniscan gadodiamide and Optimark gadoversetamide. The move comes after the agency's safety review associated the drugs with a greater risk of nephrogenic systemic fibrosis (NSF)...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >